Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 287

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 287
---
 insure an office holder against any of the following:

| ● | a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company; |

| ● | a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; |

| ● | an act or omission committed with intent to derive unlawful personal benefit; or |

| ● | a fine or forfeit levied against the office holder. |

Under the Companies Law, exculpation,
indemnification and insurance of office holders must be approved by the compensation committee and the board of directors and, with respect
to certain office holders or under certain circumstances, also by the shareholders, as described under “Management—Exculpation,
Insurance and Indemnification of Office Holders” above.

Our amended and restated articles
of association to be in effect upon completion of this offering permit us to exculpate, indemnify and insure our office holders to the
fullest extent permitted by the Companies Law and Securities Law. Each of our office holders have entered into an indemnification agreement
exculpating them, to the fullest extent permitted by Israeli law, from liability to us for damages caused to us as a result of a breach
of the duty of care and undertaking to indemnify them to the fullest extent permitted by Israeli law, including with respect to liabilities
resulting from certain acts performed by such office holders in their capacity as an office holder of the Company, our subsidiaries or
our affiliates. The indemnification is limited both in terms of amount and coverage.

In the opinion of the SEC,
indemnification of directors and office holders for liabilities arising under the Securities Act, however, is against public policy and
therefore unenforceable.

<div align='center'>II-2</div>

Item 7. Recent Sales of Unregistered Securities.

The following list sets forth
information as to all securities we have sold since March 2022, which were not registered under the Securities Act.

Between August 2020 and February
2021, we entered into several convertible loan agreements for total consideration of $900,000, or the 2020 CLAs. In October 2024, we proposed
to the lenders under the 2020 CLAs to increase the principal